NCT06527846Active, not recruiting
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Post Marketing Surveillance on Long Term Use of JARDIANCE® Tablets in Patients With Chronic Kidney Disease in Japan
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1024 (actual)
- First submitted
- 26 Jul 2024
- Start date
- 22 Oct 2024
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Chronic kidney disease
- NCT number
- NCT06527846
What you commit to
- Study type: Observational
- Participants enrolled: 1024
- From 22 Oct 2024 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to the current Japanese package insert and who provided written informed consent prior to enrolment in this study.
- Patients who have never been treated with JARDIANCE® Tablets (including treatment for Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) before enrolment.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nippon Boehringer Ingelheim Co., Ltd. Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.